2007 National Conference on Tobacco or Health

Wednesday, October 24, 2007 - 3:30 PM
Room 200 J

New Advances in the Science of Tobacco Addiction

Laura Bierut, MD, Washington University School of Medicine, Department of Psychiatry, bierutl@msnotes.wustl.edu, Jon-Jar Zubieta, MD PhD, University of Michigan, zubieta@umich.edu, Thomas R. Kosten, MD, Baylor College of Medicine, Director, Division of Alcohol and Addictive Disorders, Kosten@bcm.tmc.edu, Cora Lee Wetherington, PhD, National Institute on Drug Abuse, cwetheri@nida.nih.gov, Douglas Jorenby, PhD, University of Wisconsin School of Medicine and Public Health, Dej@ctri.medicine.wisc.edu, Cora Lee Wetherington, PhD, cwetheri@nida.nih.gov, Allison Chausmer, PhD, achausme@nida.nih.gov.

Learning Objectives: understand how tobacco smoke interacts with the mu-opioid system in the brain understand the newly-approved smoking cessation pharmacotherapy, varenicline (Chantix) understand the potential utility and limitations of anti-addiction vaccines

Audience: Interest for this symposium should cut across the meeting participants.

Key Points: There are some promising new advances in the science of tobacco addiction. This symposium seeks to take a translational approach to basic human research, emphasizing how this research could be incorporated into understanding nicotine's effects and inform treatment interventions. Dr. Jon-Kar Zubieta will discuss emerging evidence that smoking interacts with endogenous opiate systems in the human brain. Dr. Bierut will discuss genetic risk factors for nicotine addiction. Dr. Kosten will discuss anti-addiction vaccines as potential new medications for nicotine addiction. Dr. Jorenby will discuss varenicline as a new smoking cessation pharmacotherapy.

Learning Objectives: 1) Understand how tobacco smoke interacts with the mu-opioid system in the brain 2) understand the newly-approved smoking cessation pharmacotherapy, varenicline (Chantix) 3) understand the potential utility and limitations of anti-addiction vaccines

Benefits: Attendees will hear about progress being made in understanding nicotine addiction, and about some potential future pharmacotherapies for smoking cessation.


See more of New Advances in the Science of Tobacco Addiction
See more of Cessation, Nicotine, and the Science of Addiction

See more of The 2007 National Conference on Tobacco or Health (October 24-26, 2007)